Achieve Life Sciences (ACHV) Set to Post Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.20) per share and revenue of $10.65 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings data on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.64). On average, analysts expect Achieve Life Sciences to post ($0.92) EPS for the current fiscal year and ($0.57) EPS for the next fiscal year.

Achieve Life Sciences Stock Down 3.2%

NASDAQ:ACHV opened at $6.61 on Tuesday. The firm’s 50 day simple moving average is $7.42 and its 200 day simple moving average is $5.66. The company has a debt-to-equity ratio of 0.87, a current ratio of 0.95 and a quick ratio of 0.95. Achieve Life Sciences has a one year low of $2.62 and a one year high of $8.64. The company has a market cap of $680.18 million, a PE ratio of -4.26 and a beta of 2.30.

Insider Buying and Selling at Achieve Life Sciences

In related news, Director Richard Stewart sold 20,626 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $8.49, for a total transaction of $175,114.74. Following the transaction, the director owned 208,249 shares in the company, valued at $1,768,034.01. The trade was a 9.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Morgan Stanley initiated coverage on shares of Achieve Life Sciences in a research note on Thursday, August 13th. They set an “overweight” rating and a $13.00 price target for the company. Raymond James Financial reissued a “strong-buy” rating and issued a $18.00 price objective on shares of Achieve Life Sciences in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Wednesday, August 19th. Stifel Nicolaus set a $18.00 target price on Achieve Life Sciences and gave the stock a “buy” rating in a report on Tuesday, September 29th. Finally, UBS Group reiterated a “buy” rating on shares of Achieve Life Sciences in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Achieve Life Sciences has a consensus rating of “Buy” and a consensus target price of $15.50.

About Achieve Life Sciences

Achieve Life Sciences, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cytisinicline, a therapy designed to help adults quit smoking and overcome nicotine addiction. Cytisinicline is an oral, plant-based small molecule that partially activates nicotinic acetylcholine receptors, with the goal of reducing nicotine cravings and withdrawal symptoms.

The company has evaluated cytisinicline in clinical studies involving adults who smoke cigarettes, including trials assessing smoking cessation and cessation of electronic cigarette use.